PCIA
KRYS icon

Prime Capital Investment Advisors’s Krystal Biotech KRYS Stock Holding History

Prime Capital Investment Advisors’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-4,504
Closed -$812K – 1045
2025
Q1 		$812K Buy
+4,504
New +$758K 0.01% 546
2024
Q4 		– Sell
-2,591
Closed -$472K – 952
2024
Q3 		$472K Buy
2,591
+1,249
+93% +$241K 0.01% 608
2024
Q2 		$246K Buy
+1,342
New +$225K ﹤0.01% 789
2024
Q1 		– Sell
-2,498
Closed -$310K – 1034
2023
Q4 		$310K Buy
+2,498
New +$277K ﹤0.01% 727

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Prime Capital Investment Advisors's KRYS Position: Q2 2025 in Review

Prime Capital Investment Advisors sold out of Krystal Biotech (KRYS) in Q2 2025, closing a stake of 4,504 shares — an estimated $812K sold.

Prime Capital Investment Advisors first reported a position in KRYS in Q4 2023 and held it in 4 quarters. The position peaked at $812K in Q1 2025. 275 funds tracked by Wall St. Rank hold KRYS as of Q2 2025.

  • Prime Capital Investment Advisors reported no remaining Krystal Biotech position as of Q2 2025 after selling out during the quarter.
  • Prime Capital Investment Advisors sold 4,504 Krystal Biotech shares in Q2 2025, an estimated $812K.
  • Prime Capital Investment Advisors first reported a position in Krystal Biotech in Q4 2023 and held it in 4 quarters.
  • Prime Capital Investment Advisors's Krystal Biotech position peaked at $812K in Q1 2025.
  • 275 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2025.

Based on Prime Capital Investment Advisors's 13F filing for Q2 2025, filed 23 Jul 2025.